Janus kinase inhibitors for alopecia areata: A narrative review

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• The Janus kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) pathway is implicated in alopecia areata pathogenesis.
• This pathway represents a significant therapeutic target for managing alopecia areata.

Purpose of the Study:

• To provide a narrative review of Janus kinase (JAK) inhibitors for alopecia areata treatment.
• To summarize current evidence on the efficacy and limitations of JAK inhibitors in alopecia areata.

Main Methods:

• Review of clinical trials and smaller studies on JAK inhibitors in alopecia areata.
• Analysis of data for oral and topical JAK inhibitors, including FDA-approved and investigational agents.

Main Results:

• Oral JAK inhibitors, including baricitinib, tofacitinib, ruxolitinib, and ritlecitinib, have shown efficacy in promoting hair regrowth and remission.
• These agents are effective even in patients with treatment-refractory alopecia areata.
• Topical JAK inhibitors have shown limited success, with several trials terminated early.

Conclusions:

• Janus kinase (JAK) inhibitors are a valuable therapeutic option for refractory alopecia areata.
• Further research is required to assess long-term safety, topical JAK inhibitor efficacy, and predictive biomarkers for treatment response.